{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T04:41:27Z","timestamp":1789879287717,"version":"4.0.1"},"reference-count":37,"publisher":"Elsevier BV","issue":"47","license":[{"start":{"date-parts":[[2011,11,1]],"date-time":"2011-11-01T00:00:00Z","timestamp":1320105600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,11,1]],"date-time":"2011-11-01T00:00:00Z","timestamp":1320105600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2013,7,16]],"date-time":"2013-07-16T00:00:00Z","timestamp":1373932800000},"content-version":"vor","delay-in-days":623,"URL":"http:\/\/creativecommons.org\/licenses\/by\/3.0\/"}],"funder":[{"DOI":"10.13039\/501100000265","name":"UK Medical Research Council","doi-asserted-by":"crossref","award":["G0701217"],"award-info":[{"award-number":["G0701217"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2011,11]]},"DOI":"10.1016\/j.vaccine.2011.09.021","type":"journal-article","created":{"date-parts":[[2011,9,22]],"date-time":"2011-09-22T08:21:41Z","timestamp":1316679701000},"page":"8585-8590","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":57,"title":["Neutralization of non-vaccine human papillomavirus pseudoviruses from the A7 and A9 species groups by bivalent HPV vaccine sera"],"prefix":"10.1016","volume":"29","author":[{"given":"Eve","family":"Draper","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara L.","family":"Bissett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Howell-Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debbie","family":"Edwards","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graham","family":"Munslow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kate","family":"Soldan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Beddows","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2011.09.021_bib0005","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1146\/annurev.micro.112408.134019","article-title":"Vaccines to prevent infections by oncoviruses","volume":"64","author":"Schiller","year":"2010","journal-title":"Annu Rev Microbiol"},{"issue":"6","key":"10.1016\/j.vaccine.2011.09.021_bib0010","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1056\/NEJMoa021641","article-title":"Epidemiologic classification of human papillomavirus types associated with cervical cancer","volume":"348","author":"Munoz","year":"2003","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.vaccine.2011.09.021_bib0015","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1002\/ijc.25396","article-title":"Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: variation by geographical region, histological type and year of publication","volume":"128","author":"Li","year":"2010","journal-title":"Int J Cancer"},{"issue":"9686","key":"10.1016\/j.vaccine.2011.09.021_bib0020","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S0140-6736(09)61248-4","article-title":"Efficacy of human papillomavirus (HPV)-16\/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women","volume":"374","author":"Paavonen","year":"2009","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.vaccine.2011.09.021_bib0025","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1158\/1940-6207.CAPR-09-0031","article-title":"A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (types 6\/11\/16\/18) vaccine against high-grade cervical and external genital lesions","volume":"2","author":"Kjaer","year":"2009","journal-title":"Cancer Prev Res (Phila)"},{"issue":"25","key":"10.1016\/j.vaccine.2011.09.021_bib0030","doi-asserted-by":"crossref","first-page":"11553","DOI":"10.1073\/pnas.92.25.11553","article-title":"Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas","volume":"92","author":"Suzich","year":"1995","journal-title":"Proc Natl Acad Sci USA"},{"issue":"6","key":"10.1016\/j.vaccine.2011.09.021_bib0035","doi-asserted-by":"crossref","first-page":"3959","DOI":"10.1128\/jvi.69.6.3959-3963.1995","article-title":"Immunization with viruslike particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection","volume":"69","author":"Breitburd","year":"1995","journal-title":"J Virol"},{"issue":"1 Suppl.","key":"10.1016\/j.vaccine.2011.09.021_bib0040","doi-asserted-by":"crossref","first-page":"S8","DOI":"10.1016\/j.ygyno.2010.04.003","article-title":"Measuring serum antibody to human papillomavirus following infection or vaccination","volume":"118","author":"Frazer","year":"2010","journal-title":"Gynecol Oncol"},{"issue":"1 Suppl.","key":"10.1016\/j.vaccine.2011.09.021_bib0045","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/j.ygyno.2010.04.002","article-title":"Potential mechanisms for HPV vaccine-induced long-term protection","volume":"118","author":"Stanley","year":"2010","journal-title":"Gynecol Oncol"},{"issue":"2","key":"10.1016\/j.vaccine.2011.09.021_bib0050","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1086\/599988","article-title":"Immunogenicity testing in human papillomavirus virus-like-particle vaccine trials","volume":"200","author":"Schiller","year":"2009","journal-title":"J Infect Dis"},{"issue":"5722","key":"10.1016\/j.vaccine.2011.09.021_bib0055","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1126\/science.308.5722.618","article-title":"Public health. High hopes and dilemmas for a cervical cancer vaccine","volume":"308","author":"Cohen","year":"2005","journal-title":"Science"},{"issue":"29\u201330","key":"10.1016\/j.vaccine.2011.09.021_bib0060","doi-asserted-by":"crossref","first-page":"3608","DOI":"10.1016\/j.vaccine.2008.04.074","article-title":"Evaluation of systemic and mucosal anti-HPV16 and anti-HPV18 antibody responses from vaccinated women","volume":"26","author":"Kemp","year":"2008","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.vaccine.2011.09.021_bib0065","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/S1470-2045(09)70096-8","article-title":"A review of human carcinogens. Part B. Biological agents","volume":"10","author":"Bouvard","year":"2009","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.vaccine.2011.09.021_bib0070","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.virol.2004.03.033","article-title":"Classification of papillomaviruses","volume":"324","author":"de Villiers","year":"2004","journal-title":"Virology"},{"issue":"1","key":"10.1016\/j.vaccine.2011.09.021_bib0075","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.virol.2010.02.002","article-title":"Classification of papillomaviruses (PVs) based on 189 PV types and proposal of taxonomic amendments","volume":"401","author":"Bernard","year":"2010","journal-title":"Virology"},{"issue":"7","key":"10.1016\/j.vaccine.2011.09.021_bib0080","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1086\/597309","article-title":"The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16\u201326 years","volume":"199","author":"Wheeler","year":"2009","journal-title":"J Infect Dis"},{"issue":"7","key":"10.1016\/j.vaccine.2011.09.021_bib0085","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1086\/597307","article-title":"The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16\u201326 years","volume":"199","author":"Brown","year":"2009","journal-title":"J Infect Dis"},{"issue":"10","key":"10.1016\/j.vaccine.2011.09.021_bib0090","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1128\/CVI.00197-08","article-title":"Neutralizing antibodies against human papillomavirus types 16, 18, 31, 52, and 58 in serum samples from women in Japan with low-grade cervical intraepithelial neoplasia","volume":"15","author":"Ochi","year":"2008","journal-title":"Clin Vaccine Immunol"},{"issue":"11","key":"10.1016\/j.vaccine.2011.09.021_bib0095","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1093\/jnci\/djp106","article-title":"Concatenated multitype L2 fusion proteins as candidate prophylactic pan-human papillomavirus vaccines","volume":"101","author":"Jagu","year":"2009","journal-title":"J Natl Cancer Inst"},{"issue":"11","key":"10.1016\/j.vaccine.2011.09.021_bib0100","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1016\/j.vaccine.2011.01.001","article-title":"HPV16\/18 L1 VLP vaccine induces cross-neutralizing antibodies that may mediate cross-protection","volume":"29","author":"Kemp","year":"2011","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.vaccine.2011.09.021_bib0105","doi-asserted-by":"crossref","first-page":"109","DOI":"10.4161\/hv.3.4.4058","article-title":"Antibodies from women immunized with gardasil ((R)) cross-neutralize HPV 45 pseudovirions","volume":"3","author":"Smith","year":"2007","journal-title":"Hum Vaccin"},{"issue":"3","key":"10.1016\/j.vaccine.2011.09.021_bib0110","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1128\/CVI.00489-10","article-title":"Human papillomavirus 16 (HPV 16) and HPV 18 antibody responses measured by pseudovirus neutralization and competitive Luminex assays in a two- versus three-dose HPV vaccine trial","volume":"18","author":"Krajden","year":"2011","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2011.09.021_bib0115","series-title":"Immunisation against infectious disease \u2013 \u2018The Green Book\u2019","article-title":"Human papillomavirus (HPV)","author":"UK Department of Health","year":"2011"},{"key":"10.1016\/j.vaccine.2011.09.021_bib0120","doi-asserted-by":"crossref","DOI":"10.1002\/0471143030.cb2601s37","article-title":"Production of papillomavirus-based gene transfer vectors","author":"Buck","year":"2007","journal-title":"Curr Protoc Cell Biol"},{"issue":"2","key":"10.1016\/j.vaccine.2011.09.021_bib0125","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.virol.2003.12.027","article-title":"Reactivity of human sera in a sensitive, high-throughput pseudovirus-based papillomavirus neutralization assay for HPV16 and HPV18","volume":"321","author":"Pastrana","year":"2004","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2011.09.021_bib0130","first-page":"445","article-title":"Generation of HPV pseudovirions using transfection and their use in neutralization assays","volume":"119","author":"Buck","year":"2005","journal-title":"Methods Mol Med"},{"issue":"7","key":"10.1016\/j.vaccine.2011.09.021_bib0135","doi-asserted-by":"crossref","first-page":"e69","DOI":"10.1371\/journal.ppat.0020069","article-title":"Carrageenan is a potent inhibitor of papillomavirus infection","volume":"2","author":"Buck","year":"2006","journal-title":"PLoS Pathog"},{"issue":"24","key":"10.1016\/j.vaccine.2011.09.021_bib0140","doi-asserted-by":"crossref","first-page":"12961","DOI":"10.1128\/JVI.77.24.12961-12967.2003","article-title":"Further evidence that papillomavirus capsids exist in two distinct conformations","volume":"77","author":"Selinka","year":"2003","journal-title":"J Virol"},{"issue":"5","key":"10.1016\/j.vaccine.2011.09.021_bib0145","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1128\/JVI.02190-08","article-title":"Role of heparan sulfate in attachment to and infection of the murine female genital tract by human papillomavirus","volume":"83","author":"Johnson","year":"2009","journal-title":"J Virol"},{"issue":"9518","key":"10.1016\/j.vaccine.2011.09.021_bib0150","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1016\/S0140-6736(06)68439-0","article-title":"Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial","volume":"367","author":"Harper","year":"2006","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.vaccine.2011.09.021_bib0155","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.jadohealth.2008.10.002","article-title":"Immunogenicity and safety of human papillomavirus (HPV)-16\/18 AS04-adjuvanted vaccine in healthy boys aged 10\u201318 years","volume":"44","author":"Petaja","year":"2009","journal-title":"J Adolesc Health"},{"issue":"27\u201328","key":"10.1016\/j.vaccine.2011.09.021_bib0160","doi-asserted-by":"crossref","first-page":"5571","DOI":"10.1016\/j.vaccine.2006.04.068","article-title":"Immunologic responses following administration of a vaccine targeting human papillomavirus types 6, 11, 16, and 18","volume":"24","author":"Villa","year":"2006","journal-title":"Vaccine"},{"issue":"37","key":"10.1016\/j.vaccine.2011.09.021_bib0165","doi-asserted-by":"crossref","first-page":"4795","DOI":"10.1016\/j.vaccine.2008.07.002","article-title":"Rationale and design of a community-based double-blind randomized clinical trial of an HPV 16 and 18 vaccine in Guanacaste, Costa Rica","volume":"26","author":"Herrero","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2011.09.021_bib0170","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1038\/sj.bjc.6603955","article-title":"Prevalence of human papillomavirus antibodies in young females in England","volume":"97","author":"Jit","year":"2007","journal-title":"Br J Cancer"},{"issue":"38","key":"10.1016\/j.vaccine.2011.09.021_bib0175","doi-asserted-by":"crossref","first-page":"6247","DOI":"10.1016\/j.vaccine.2010.07.007","article-title":"Sustained efficacy and immunogenicity of the HPV-16\/18 AS04-adjuvanted vaccine up to 7.3 years in young adult women","volume":"28","author":"De Carvalho","year":"2010","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.vaccine.2011.09.021_bib0180","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1086\/589862","article-title":"Vaccines: correlates of vaccine-induced immunity","volume":"47","author":"Plotkin","year":"2008","journal-title":"Clin Infect Dis"},{"issue":"7","key":"10.1016\/j.vaccine.2011.09.021_bib0185","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1128\/CVI.00131-10","article-title":"Correlates of protection induced by vaccination","volume":"17","author":"Plotkin","year":"2010","journal-title":"Clin Vaccine Immunol"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X11014277?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X11014277?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:17:55Z","timestamp":1759400275000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X11014277"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,11]]},"references-count":37,"journal-issue":{"issue":"47","published-print":{"date-parts":[[2011,11]]}},"alternative-id":["S0264410X11014277"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2011.09.021","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2011,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Neutralization of non-vaccine human papillomavirus pseudoviruses from the A7 and A9 species groups by bivalent HPV vaccine sera","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2011.09.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}